-
Je něco špatně v tomto záznamu ?
Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer's Disease
L. Cahlíková, R. Vrabec, F. Pidaný, R. Peřinová, N. Maafi, AA. Mamun, A. Ritomská, V. Wijaya, G. Blunden
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
GA UK 328121; SVV UK 260 548
Grantová Agentura, Univerzita Karlova
reg. No. CZ.02.1.01/0.0/0.0/18_069/0010046
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- alkaloidy amarylkovitých metabolismus MeSH
- Alzheimerova nemoc metabolismus MeSH
- Amaryllidaceae chemie MeSH
- neurodegenerativní nemoci metabolismus MeSH
- prolyloligopeptidasy metabolismus MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease recognized as the most common form of dementia among elderly people. Due to the fact that the exact pathogenesis of AD still remains to be fully elucidated, the treatment is only symptomatic and available drugs are not able to modify AD progression. Considering the increase in life expectancy worldwide, AD rates are predicted to increase enormously, and thus the search for new AD drugs is urgently needed. Due to their complex nitrogen-containing structures, alkaloids are considered to be promising candidates for use in the treatment of AD. Since the introduction of galanthamine as an antidementia drug in 2001, Amaryllidaceae alkaloids (AAs) and further isoquinoline alkaloids (IAs) have been one of the most studied groups of alkaloids. In the last few years, several compounds of new structure types have been isolated and evaluated for their biological activity connected with AD. The present review aims to comprehensively summarize recent progress on AAs and IAs since 2010 up to June 2021 as potential drugs for the treatment of AD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003884
- 003
- CZ-PrNML
- 005
- 20220127145749.0
- 007
- ta
- 008
- 220113s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules26175240 $2 doi
- 035 __
- $a (PubMed)34500673
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Cahlíková, Lucie $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 245 10
- $a Recent Progress on Biological Activity of Amaryllidaceae and Further Isoquinoline Alkaloids in Connection with Alzheimer's Disease / $c L. Cahlíková, R. Vrabec, F. Pidaný, R. Peřinová, N. Maafi, AA. Mamun, A. Ritomská, V. Wijaya, G. Blunden
- 520 9_
- $a Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease recognized as the most common form of dementia among elderly people. Due to the fact that the exact pathogenesis of AD still remains to be fully elucidated, the treatment is only symptomatic and available drugs are not able to modify AD progression. Considering the increase in life expectancy worldwide, AD rates are predicted to increase enormously, and thus the search for new AD drugs is urgently needed. Due to their complex nitrogen-containing structures, alkaloids are considered to be promising candidates for use in the treatment of AD. Since the introduction of galanthamine as an antidementia drug in 2001, Amaryllidaceae alkaloids (AAs) and further isoquinoline alkaloids (IAs) have been one of the most studied groups of alkaloids. In the last few years, several compounds of new structure types have been isolated and evaluated for their biological activity connected with AD. The present review aims to comprehensively summarize recent progress on AAs and IAs since 2010 up to June 2021 as potential drugs for the treatment of AD.
- 650 _2
- $a Alzheimerova nemoc $x metabolismus $7 D000544
- 650 _2
- $a Amaryllidaceae $x chemie $7 D000070378
- 650 _2
- $a alkaloidy amarylkovitých $x metabolismus $7 D047151
- 650 _2
- $a neurodegenerativní nemoci $x metabolismus $7 D019636
- 650 _2
- $a prolyloligopeptidasy $x metabolismus $7 D000085822
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vrabec, Rudolf $u Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Pidaný, Filip $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Peřinová, Rozálie $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Maafi, Negar $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Mamun, Abdullah Al $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Ritomská, Aneta $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Wijaya, Viriyanata $u ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Blunden, Gerald $u School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire P01 2DT, UK
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 26, č. 17 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34500673 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145746 $b ABA008
- 999 __
- $a ok $b bmc $g 1751369 $s 1155033
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 26 $c 17 $e 20210829 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a GA UK 328121; SVV UK 260 548 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a reg. No. CZ.02.1.01/0.0/0.0/18_069/0010046 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20220113
